Clinical management of lipid metabolism abnormalities induced by antipsychotics in closed psychiatric settings: challenges and integrated strategies
Abstract
In closed psychiatric settings, antipsychotic-induced lipid metabolism abnormalities pose significant clinical challenges. Constrained by limited patient mobility, fluctuating treatment adherence, and monotonous diets, traditional management struggles to adequately balance drug side effects with patient health needs. This study presents an integrated framework involving surveillance, intervention, and interdisciplinary collaboration. It includes a comprehensive "admission-to-intervention" monitoring system, low-glycemic diet combined with portion control, symptom-specific exercise programs, and strategies to improve treatment adherence. We establish quality metrics, including 100% baseline lipid testing for new admissions and ≥ 95% timely intervention rate for abnormalities. The patient-centered model reduces cardiovascular risks, improves patient outcomes, and offers a scalable approach for metabolic health management in resource-limited environments.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.